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Abstract: Stroke is one of the main causes of death and disability in the world. Cardioembolic etiology accounts for ap-
proximately one fifth of all ischemic strokes whereas 25-30% remains undetermined even after an advanced diagnostic 
workup. Despite there is not any biomarker currently approved to distinguish cardioembolic stroke among other etiologies 
in clinical practice the use of biomarkers represents a promising valuable complement to determine stroke etiology reduc-
ing the number of cryptogenic strokes and aiding in the prescription of the most appropriated primary and secondary 
treatments in order to minimize therapeutic risks and to avoid recurrences. In this review we present an update about spe-
cific cardioembolic stroke-related biomarkers at a protein, transcriptomic and genetic level. Finally, we also focused on 
reported biomarkers associated with atrial fibrillation (a cardiac illness strongly related with cardioembolic stroke sub-
type) thus with a potential to become biomarkers to detect cardioembolic stroke in the future. 
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INTRODUCTION 
 Stroke remains one of the most important neurological 
affection representing the second leading cause of prevent-
able death and being one of the major causes of productiv-
ity impairment. In the US, on average, every 40 seconds, 
someone has a stroke and annually, 5.5 million people die 
worldwide, with 44 million disability-adjusted life-years 
lost [1, 2]. Furthermore, the prevalence of stroke is ex-
pected to become significantly larger as the world popula-
tion older than 65 is increasing by 9 million people per year 
[3].  
 There exist two principle acute stroke subtypes. The main 
one, representing over 80-85% of all strokes, is ischemic 
stroke caused by brain arterial occlusion. On the other hand, 
15-20% are due to bleeding into the brain as a consequence 
of an arterial rupture [1]. At present, stroke diagnosis is 
mainly based on clinical criteria supplemented by imaging 
data. In most countries, once diagnosed patients with acute 
ischemic stroke are treated with intravenous recombinant 
tissue plasminogen activator (r-tPA), a serine protease, as 
primary therapy. Unfortunately, with a narrow effective 
therapeutic time window of only 4.5 h, an early diagnostic 
becomes essential. Moreover, after overcoming diagnosis 
and hyperacute treatment, an accurate etiological classifica-
tion is critical not only during the acute phase and its pri-
mary therapy, but also and mainly to select a suitable secon-
dary treatment.  
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MAJOR STROKE ETIOLOGY CLASSIFICATION 
SYSTEMS 
 Since the Harvard Stroke Regisitry development in 1978 
[4], several classifications of stroke subtypes have been de-
veloped, being the TOAST (Trial of Org 10172 in Acute 
Stroke Treatment) classification system the most widely 
used nowadays for stroke subtyping. The TOAST classifica-
tion system determines five major subtypes of ischemic 
stroke: cardioembolic stroke (CE), large artery atherotrom-
botic stroke (LAA), small vessel disease (SVD), stroke of 
other determined cause (SOC) and stroke of undetermined 
cause [5]. As well as TOAST, all the other classification 
systems group patients into different main categories being, 
in some cases, further sub-classified in other subtypes. Using 
some of the currently available stroke classification systems 
there is an evident oversizing and a great heterogeneity of 
the undetermined category, especially in the eldest ones. 
This might probably be a direct consequence of the unavail-
ability of modern diagnostic tools by the time that these clas-
sification systems were developed, hindering a complete 
evaluation of the patient [4-6].  
 In contrast, new classifications such as SSS-TOAST, its 
automated version CCS (Causative Classification of Stroke 
System) [7, 8], the Korean TOAST [9] and ASCO (Athero-
sclerosis, Small-vessel disease, Cardiac source, Other cause) 
[10, 11], have been developed taking into account underlying 
diseases associated with stroke and the existence of different 
phenotypes. As a consequence, the rate of strokes with an 
undetermined cause has been clearly reduced with the new-
est stroke classification systems when compared with the 
eldest ones. 
 The latest classification system, CISS (Chinese Ischemic 
Stroke Subtype Subclassification), is a two step system 
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which was conceived in 2011. CISS first step aims at the 
etiology, considering five TOAST-based categories but in-
cluding more accurate subgroups, whereas the second step 
classifies stroke patients by the mechanism that underlies the 
ischemic event [12]. Even though considering both etiologi-
cal and pathophysiological causes of stroke, one of the most 
important limiting conditions of the CISS classification sys-
tem is its dependence on modern imaging technology avail-
ability.  
STROKE MANAGEMENT REGARDING ETIOLOGI-
CAL SUBTYPES 
 Depending on the causes of the artery occlusion patients 
might be differently managed in the stroke unit. If the 
thrombus has a cardiac or atherosclerotic origin, those af-
fected individuals who fulfil the inclusion criteria receive r-
tPA as a primary treatment. On the contrary there exists con-
troversy about thrombolysis on patients with lacunar strokes. 
Some authors are against the administration of intravenous r-
tPA in patients without demonstrated artery occlusion [13], 
whereas others propose thrombolysis even on the presence of 
an undetectable fibrin clot in the arteriole [14, 15]. In addi-
tion, as hemorrhagic transformation risk is related to the vol-
ume of the infarcted tissue [16], that risk might be reduced in 
lacunar strokes. Nevertheless the degree to which throm-
bolytic primary therapy may improve outcome in these pa-
tients is still uncertain [17]. 
 Regarding secondary prevention therapy, patients will 
receive different treatment depending on etiology: cardioem-
bolic strokes are usually treated with anticoagulant drugs 
whereas atherosclerotic strokes follow an antiplatelet therapy 
or even surgery (e.g. carotid endarterectomy). Similarly anti-
platelet agents are the treatment of choice for lacunar 
strokes, together with antihypertensive drugs.  
 In spite of the importance of the accurate stroke subtype 
classification, the etiology of approximately 30% of all 
stroke cases remains unknown even after a precise and ad-
vanced diagnostic workup has been conducted [18]. The use 
of biomarkers would ease the lowering of the rate of crypto-
genic strokes and also could contribute to speed up the diag-
nostic process prescribing the most appropriated primary and 
secondary treatments in order to minimize therapeutic risks 
and to avoid recurrences. 
BIOMARKERS OF CARDIOEMBOLIC STROKE  
 Stroke caused by cardiac embolism accounts for ap-
proximately one fifth of ischemic strokes each year and 6-
12% patients experience recurrences within 2 weeks after the 
first embolism [19]. Thrombus formation in the cardiac 
chambers is mainly caused by blood stasis, leading to a fi-
brin rich clot which may be then ejected towards the arterial 
circulation. Cerebral ischemia appears when the blood flow 
through a cerebral artery turns impaired by this thrombus.  
 One of the purposes of the stroke etiological classifica-
tion systems is to classify patients for the therapeutic deci-
sion-making but, in spite of their usefulness, these classifica-
tion systems still have important limitations (i.e. high rates 
of undetermined etiology, neuroimaging dependence). Bio-
markers of stroke etiology might have a great importance in 
the development of more precise and reliable classification 
schemes which may serve as a valuable research and diag-
nostic tool [20]. 
 This review presents an update of the research done in 
stroke biomarkers focusing on the possibility of identifying 
stroke of cardioembolic etiology since a more aggressive 
management will reduce dramatically stroke recurrence 
rates. For that we performed a search in Medline database 
introducing the terms cardioembolic stroke AND biomarker 
and selected data on different available biomarkers that may 
be measured in blood, such as proteins and circulating mi-
croRNAs, or analyzed at genetic level as gene expression 
profile or polymorphisms. 
 The most promising candidates to become biological 
markers for each stroke etiology are supposed to play a role 
in the pathophysiology of each stroke subtype (i. e. hemosta-
sis, inflammation, immune system activation, endothelial 
damage or oxidative stress) [21]. Unfortunately several of 
these processes underlie in more than one stroke etiology, 
highlighting the complexity of the cerebrovascular disease. 
What is more, biomarkers might not even be specific to 
stroke since other clinical conditions, such as myocardial 
infarction, have common underlying pathophysiological 
mechanisms. Thus non-specific biomarkers should be em-
ployed with caution and this may hamper the application of 
these biomarkers in daily clinical practice. The most relevant 
studied biomarkers and their association with stroke etiolo-
gies are summarized in (Fig. 1). 
STROKE ETIOLOGY AND CIRCULATING PRO-
TEINS  
 In the subsections below we will focus on protein bio-
markers associated with cardioembolic stroke grouped by the 
underlying pathophysiological mechanism. The biomarkers 
discussed are represented in (Fig. 2) and classified by the 
pathophysiologic mechanism they are involved in.  
Coagulation and Fibrinolytic Systems 
 Coagulation and fibrinolytic mechanisms are activated as 
a physiologic response after ischemia. D-dimer, a breakdown 
product of fibrin, is one of the basic markers of fibrinolytic 
system activity. It is not only elevated in plasma taken from 
patients with atrial fibrillation (AF) -most common cardiac 
abnormality leading to stroke- but also has been found raised 
in CE stroke patients compared with other etiologies [22-24]. 
A recent study, conducted by Alvarez-Perez and collabora-
tors with 200 stroke patients and 50 controls, shows a 
thrombogenic profile in patients with CE stroke character-
ized by higher D-dimer levels than LAA, SVD or undeter-
mined etiologies (p<0.0001) [25].  
 Raised fibrinogen and D-dimer/fibrinogen ratio in pa-
tients with CE stroke (p<0.0001 vs controls and patients with 
LAA and SVD strokes; p=0.004 vs patients with undeter-
mined stroke) were also found in this study. D-dimer to-
gether with other hemostatic biomarkers, such as thrombin-
antithrombin III complex (TAT), fibrinogen, fi-
brin/fibrinogen degradation products (FDPs), fibrin mono-
mer complex (FMC) and soluble fibrin (SF), have been as-
sayed lately among different subtypes of stroke [26]. CE 
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stroke patients showed higher levels of FMC, SF, D-dimer 
and FDP than non-CE patients (LAA, SVD and others, 
p<0.05) after one day of hospitalization while fibrinogen was 
increased in LAA strokes when compared to CE. FMC and 
SF levels (both markers indicative of hypercoagulable state) 
were still different (p<0.05) two days after stroke onset, but 
regarding FDP (indicative of hyperfibrinolytic state), these 
differences remained even 7 days after stroke. Thus, meas-
urement of these three hemostatic biomarkers could aid in 
the differentiation of CE and non-CE strokes in both acute 
and subacute phases. 
 Other markers for CE stroke have been further investi-
gated. B-type natriuretic peptide (BNP) has an antifibrotic 
role in the heart and acts as a cardiac hormone. BNP is the 
main product of the cleavage of propeptide (proBNP), which 
also equimolarly release N-terminal peptide (NT-proBNP). 
All three peptides are considered to have a similar potential 
to discern CE stroke subtype among other etiologies [27]. 
Montaner and colleagues showed an association between 
high levels of BNP and D-dimer with CE stroke [24]. Plasma 
concentrations of both proteins were determined in a cohort 
of 707 patients. BNP higher than 76 pg/ml (OR: 2.3; 95% 
CI: 1.4-3.7; p=0.001) together with D-dimer higher than 0.96 
µg/ml (OR: 2.2; 95% CI: 2.4-18.9; p=0.001) were independ-
ent predictors of CE stroke in a logistic regression model 
including NIHSS at baseline. This is important since CE 
strokes present larger infarcts and more pronounced deficits 
than other etiologies. Thus logistic-regression models should 
be adjusted by variables which reflect this involvement such 
as NIHSS, infarct size or Oxford Community Stroke Project 
classification (OCSP). More recently published studies re-
port similar relation between BNP and cardioembolism and 
further confirm previous findings [24, 28-30]. Interestingly, 
BNP has also been found to be associated with AF (OR: 2.0; 
95% CI; 1.6-2.5) in a cohort of 569 patients including all 
stroke subtypes. In the same study BNP was related with CE 
 
Fig. (1). Most relevant biomarkers grouped by specific pathophysiologies related to the three main stroke etiologies. Molecules in brackets 
have been identified in patients with AF, strongly related with cardioembolic stroke. BNP: b-type natriuretic peptide; CK-MB: creatine 
kinase isoform MB; CRP: C reactive protein; FDP: fibrin/fibrinogen degradation products; FMC: fibrin monomer complex; IL-1β: interleu-
kin 1 beta; IL-6: interleukin 6; oxLDL: oxidized low denisity lipoprotein; PDMP: plateled derived microparticles; ProANP: pro-atrial natri-
uretic peptide; RBP4: retinol binding protein; SF: soluble fibrin; sGPVI: soluble glycoprotein VI; sRAGE: soluble advanced glycation end 
products receptor ; TAT: thrombin-antithrombin complex; TFPI: tissue factor pathway inhibitor; TM: thrombomodulin; TNFα: tumour ne-
crosis factor alpha; TNFSF14: tumour necrosis factor family member 14; vWF: von Willebrand factor. 
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stroke subtype (p<0.001) and resulted an independent predic-
tor of functional outcome ((OR, 0.5; 95% CI, 0.3-0.9) and 
mortality (OR, 3.05; 95% CI, 1.1-8.2) exclusively in patients 
with CE [31]. 
 NT-proBNP has also been proposed for discerning be-
tween CE and other stroke etiologies in 92 patients with AF 
[27]. As authors discuss, NT-proBNP serum levels above 
912 pg/mL (sensitivity 55.5%, specificity 97.9%, positive 
predictive value (PPV) 90.9 %, negative predictive value 
(NPV) 83.9%) can be used to identify those patients more 
prone to have AF in undetermined strokes and consequently 
it may aid to select subjects for prolonged cardiac rhythm 
monitoring in order to confirm paroxysmal AF. These pa-
tients who would probably suffer a secondary stroke with a 
cardiac origin may benefit from anticoagulant preventive 
treatment. 
 Regarding proBNP, Rodríguez-Yáñez and colleagues 
published a study including 262 patients from all TOAST 
etiologies and showed that plasma levels over 360 pg/mL of 
this peptide were independently associated with CE stroke 
(OR: 28.51; 95% CI: 5.90-136.75; p<0.0001) in a model that 
included basal NIHSS [32]. 
 Von Willebrand Factor (vWF), a well studied hemostatic 
marker, has been found to be related with CE stroke. Raised 
levels of vWF were determined in CE patients by Licata and 
collaborators but only showed a trend (10 (5-12) ng/ml; 
p=0.0053) compared to other stroke subtypes [33]. Other 
studies showed that high levels of vWF are associated with 
AF and can predict cardiovascular events [34-36]. More re-
cently, Hanson and collaborators examined vWF levels in 
patients with CE, LAA SVD or UND stroke [37]. Subject 
with CE and LAA stroke displayed higher vWF levels than 
SVD group (253 IU/dl [95% CI 230-279] and 263 IU/dl 
[95% CI 242-286], vs. 213 UI/dl [95% CI 197-229], respec-
tively) during the acute phase, whereas at three months after 
the cerebrovascular event, only patients who suffered CE 
stroke showed higher vWF than those with SVD (240 IU/dl 
[95% CI 224-256] vs. 201 IU/dl [95% CI 189-215]). As 
authors discussed, these results agree with those from Ohira 
and colleagues, in which CE stroke patients also showed in-
creased levels of vWF than patients with SVD (p<0.05) [38]. 
 Other biological markers of cardiac damage such as pro-
atrial natriuretic peptide (pro-ANP) together with creatine 
kinase MB (CK-MB) were analyzed and reported to be 
higher in patients with CE infarcts. Authors suggested a cut-
off point of 2.6 ng/mL (sensitivity 62%, specificity 80%, 
p<0.0001) and 2266.6 fmol/mL (sensitivity 62%, specificity 
70%, p<0.0001), for each marker respectively [32]. 
 Very recently Santamarina and collaborators determined 
plasma concentrations of some of these previously studied 
biomarkers (BNP, D-dimer, CK-MB, troponin and myoglo-
bin) in a cohort of 89 selected patients with undetermined 
stroke. After cardiological work-up, 49 of these patients with 
cryptogenic stroke were diagnosed as embolic. The most 
common findings were AF, severe aortic atheromatosis, pat-
ent foramen ovale, aneurysm of atrial septum and dilated 
cardiomyopathy. Cardioembolic stroke patients had higher 
plasma concentrations of BNP (121 [24-260.5] vs 26.8 
[12.2-70.4], p=0.003), myoglobin (109 [66.9-177.7] vs 85.4 
[61.4-125], p=0.028) and CK-MB (1.45 [0.5-2.27] vs 0.5 
[0.5-1.4], p=0.004) than the ones that remained as crypto-
genic. Finally, they constructed a predictive model adjusted 
by age, gender, risk factors, heart disease and stroke severity 
where BNP and CK-MB together with suffering of a previ-
ous stroke were independently associated to embolic abnor-
malities (OR 8.06, CI 95% 2.34-27.72; OR 6.52, CI 95% 
1.44-29.5; OR 5.34, CI 95% 1.14-29.97; respectively). These 
results evidence the fact that some biomarkers contain the 
potential to improve the diagnosis of a stroke from an em-
bolic source optimizing the performance of early cardiac 
explorations in those patients with undetermined stroke [39]. 
 
Fig. (2). Illustration of the cardioembolic stroke pathophysiology and different areas represented by the biomarkers presented 
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Systemic Inflammation and Endothelial Activation 
 High serum levels of immuno-inflammatory mediators 
such as TNFα, IL-6, IL-1β, selectins and adhesion molecules 
have been associated with ischemic stroke suggesting that 
both molecular and cellular inflammation mediates the 
mechanisms of cerebral injury and repair. Several studies 
have tried to clarify the role played by inflammation in the 
pathogenesis of different stroke etiologies. Licata and col-
laborators evaluated the levels of different cytokines, select-
ins and adhesion molecules among ischemic stroke subtypes 
[33]. In this study, patients classified as CE showed higher 
concentration of TNF-α (38.5 (22.2-46) pg/ml; p<0.0001), 
IL-6 (11 (5.5-19) pg/ml; p=0.0029) and IL-1β (11.5 (8-13) 
pg/ml; p<0.0001) in plasma compared to other TOAST cate-
gories. Although systemic inflammatory state have been fur-
ther related with atherosclerosis, these results suggest that 
inflammation may also play a role in the pathological proc-
esses of cerebral cardioembolism [40]. Moreover, higher 
plasma levels of IL-18 [41], E-selectin [42], soluble vascular 
cell adhesion molecule-1 (sVCAM-I) [43], platelet factor-4 
(PF-4) [44], sP-selectin [45], Platelet Microparticles (PMP) 
[46], asymmetric and symmetric dymethylarginine (ADMA, 
SDMA) [47, 48] found in different cohorts of patients with 
AF indicates that inflammation, platelet activation and oxi-
dative stress are conditions not only related with LAA but 
might be also related with CE stroke. 
 C reactive protein (CRP) is a well-known acute phase 
reactant protein whose concentration rises in response to 
inflammation or infection. In spite of being one of the most 
studied inflammatory markers in stroke, several controver-
sial results have been reported regarding its use as etiologic 
biomarker. Terruzzi and collaborators showed higher plasma 
levels of CRP in CE stroke patients when compared with 
other TOAST subtypes within the first 6 hours after symp-
toms onset [49]. However, as CRP has been suggested to 
promote platelet activation and foam cells generation 
through macrophages differentiation, it has been associated 
with large artery atherotrombotic events [50, 51]. Álvarez-
Perez and colleagues showed a higher CRP in LAA when 
compared with SVD (p=0.010) and undetermined (p=0.003) 
strokes, but not with CE ones [52]. Adding more controversy 
to the role of CRP as etiologic biomarker, some authors de-
tected no differences in CRP serum levels between etiology 
groups [53, 54]. Alternative approaches, such as meta-
analysis or studies including greater cohorts of patients, are 
necessary to clarify the relation between CRP levels and 
different stroke etiologies. 
Endothelial Damage 
 Micro and macroangiopathy affect endothelial walls 
thickness and reduce blood flow through small and large 
vessels. These processes are strongly related with hyperten-
sion and diabetes. 
 Reduced plasma levels of soluble advanced glycation end 
products receptor (sRAGE), a cell surface molecule member 
of the immunoglobulin superfamily, are considered to be 
related with the development of microangiopathy. Plasma 
levels of this protein were compared between stroke etiolo-
gies in a total of 482 enrolled patients by Yokota and col-
laborators. Distribution of sRAGE were significantly differ-
ent among etiologies, being CE plasma concentrations the 
highest (1280 (271-4720) pg/mL, p=0.001) [55]. In this line 
of evidence, Montaner also showed significantly higher 
sRAGE levels in the group of patients with CE stroke (1.1 
(0.7-1.9) ng/ml) etiologic [24]. 
 Biomarkers which have been assayed in ischemic stroke 
patients and related with CE subtype are summarized in Ta-
ble 1. Table 2 shows the CE stroke-related biomarkers with a 
highest sensitivity and specificity found in the literature. 
OTHER CANDIDATES 
 Apart from stroke biomarkers strongly related with CE 
etiology, some other molecules are associated with high risk 
cardioembolic conditions and therefore remain as candidates 
to become markers for CE stroke. The most common of 
these cardiac conditions which may lead to a cardioembolic 
event are: atrial fibrillation, recent myocardial infarction, 
dilated myocardiopathy, and mitral rheumatic stenosis. Other 
major sources of cardioembolism are ineffective endocardi-
tis, marantic endocarditis and atrial myxoma; and patent fo-
ramen ovale, atrial septal aneurysm, atrial or ventricular sep-
tal defects, calcific aortic stenosis, and mitral annular calcifi-
cation as minor sources [56, 57]. These potential biomarkers 
of underlying pathological risks may provide ample basis for 
future studies and could become valuable indicators of 
neurovascular events allowing physicians to carry out a bet-
ter etiological classification.  
 Table 3 shows those candidates which are associated to 
AF, the most common CE stroke related cardiac affection.  
GENE EXPRESSION BIOMARKERS OF STROKE 
ETIOLOGY 
 Gene expression profile can also be used to discern be-
tween different stroke subtypes. In 2010, Jickling GC and 
colleagues reported the results of the complete CLEAR trial. 
The expression profile from a total number of 23 CE and 10 
LAA patients were compared and, as a result, 40 genes 
whose expression was significantly different among both 
etiologies were identified [58]. 11 of these 40 genes are in-
volved in cellular movement, cell-to-cell signalling and in-
teraction, and tissue development.  
 Especially interesting genes are ENPP2 (Ectonucleotide 
pyrophoshpatase/phosphodiesterase family member 2) and 
GRM5 (Glutamate receptor metabotropic 5). ENPP2 protein 
is involved in angiogenesis and neurite growth, whereas 
GRM5 encodes the glutamate receptor metabotropic 5, which 
is involved in normal brain function. Other genes such as 
LHFP, TMEM19 and EBF1 are involved in cardiac prolifera-
tion, cardiovascular development and haematological system 
function [77]. The proposed 40 genes expression profile pre-
dicted correctly 9 out of 10 patients known to be CE and 
when the same gene profile was used in 36 patients with an 
undetermined etiology, 58% of them were reclassified as CE 
or LAA with a probability greater than 90%. These results 
strongly suggest that gene expression profile could be used 
to complement diagnostic tests to determine the etiology in 
cryptogenic patients.  
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Protein Levels Regarding 
Etiology 
Main Function  Ref. 
Albumin Protein P02768 200 CE < other etiologies 
Regulates colloidal osmotic pressure of 
blood.  
[52] 




- 1300 CE > other etiologies 
ProBNP cleavage product. Cardiac hor-
mone that regulates cardiovascular homeo-
stasis.  





262 CE > other etiologies 
Mediates energy transduction in tissues. 
Increased in heart damage diseases.  
[32, 39]  
CRP* Protein P02741 985 
CE > other etiologies; LAA > 
other etiologies; no difference 
among subtypes 
Displays several functions associated with 











- 69 CE > non-CE 
Involved in coagulation/fibrinolysis proc-
esses.  
[26] 
Fibrinogen* Protein P02671 269 
CE < LAA; no difference 
among subtypes 
Yields monomers that polymerize into 






- 69 CE > non-CE 
Involved in coagulation/fibrinolysis proc-
esses.  
[26] 
IL-1β Protein P01584 227 CE > other etiologies Pro-inflammatory cytokine.  [33, 40] 




- 92 CE > non-CE 
Pro-BNP cleavage product. High levels 
may help to select stroke patients with AF. 
[27] 
Pro-BNP Protein P16860 262 CE > other etiologies 
BNP precursor. ProBNP might be useful to 
reclassify undetermined stroke as of CE 
origin. 
[32] 
S100B Protein P04271 33 CE > other etiologies 
Involved in metal-ion binding and in the 
regulation of protein phosphorylation in 
brain tissue.  
[61] 
sCD40L* Protein P29965 132 No difference among etiologies 






- 69 CE > other etiologies 
Involved in coagulation/fibrinolysis proc-
esses.  
[26] 
sRAGE Protein Q9UQ07 1189 CE > other etiologies Growth factor for several cell types.  [24,55] 
TNF-α Protein P01375 227 CE > other etiologies Pro-inflammatory cytokine.  [33,40] 
vWF Protein P04275 1551 CE and LAA > other etiologies 
Promotes platelet adhesion to the sub-
endothelial matrix. Higher in patients with 
AF. 
[33-38] 
ANP: atrial natriuretic peptide; AF: atrial fibrillation; BNP: b-type natriuretic peptide; CE: cardioembolic; CK-MB: creatine kinase MB; CRP: C-reactive protein; FDP: fi-
brin/fibrinogen degradation products, FMC: fibrin monomer complex; IL-1β: interleukin 1-beta; IL-6: interleukin 6; LAA: large artery atherosclerosis; ; NT-proBNP: N-terminal part 
of pro-BNP; Pro-BNP: proform of BNP; SF: soluble fibrin; sRAGE: soluble receptor for advanced glycation end products; SVD: small vessel disease; TNF-α: tumour necrosis factor 
alpha;  
*Candidate marker with controversial results among studies. 
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Table 2. Markers with highest sensitivity / specificity for the identification of CE stroke.  
Marker Sample Size Cutoff Point Sensitivity Specificity PPV NPV Ref .
BNP 707 >76 pg/mL 68% 72% 55% 82% [24] 
D-dimer 707 >300 ug/L 100% 52% 46% 73% [24] 
BNP combined with D-dimer 707 - 66.5% 91.3% - - [24] 
Pro-BNP 262 >360 pg/mL 87% 83% - - [32] 
ANP 262 >2266.6 fmol/mL 62% 70% - - [32] 
NT-proBNP 92 >265 pg/mL 71.4% 73.7% 77.8% 66.6% [27] 
CK-MB 89 >1.5 ng/mL 47.9% 85% 79.3% 79.3% [39] 
BNP combined with CK-MB 89 - 31.2% 95% 88.2% 53.5% [39] 
ANP: atrial natriuretic peptide; BNP: b-type natriuretic peptide; CK-MB: creatine kinase MB; NT-proBNP: N-terminal part of pro-BNP; NPV: Negative predictive value; PPV: 
Positive predictive value 
 
 On the other hand, in the same study a different 37 
genes expression profile was found to distinguish patients 
with CE stroke due to AF and non-AF causes with a prob-
ability higher than 90%. This 37 genes list may provide 
physicians an additional tool for the identification of pa-
tients more prone to suffer AF, as its detection strongly 
depends on cardiac monitoring, not always available for all 
patients. Moreover, paroxysmal AF detection requires a 
more prolonged follow-up period making more difficult the 
diagnosis of AF, thus this 37 gen expression profile analy-
sis at baseline could be very helpful to identify these indi-
viduals. 
 In a later study, the same authors followed a similar strat-
egy in a cohort of patients with lacunar and non-lacunar 
stroke. The study reported 41 genes whose expression profile 
allowed to distinguish both groups and predict etiology in 
small deep infarcts of undetermined cause [78]. 
 Finally, these two gene profiles, the 40-genes list that 
distinguished CE and LAA strokes and the 41-genes list that 
distinguished lacunar and non-lacunar strokes, were inte-
grated and combined with infarct location assessed by neuro-
imaging to predict the most probable cause of stroke in a 
cohort of 131 patients with cryptogenic strokes. Of these 131 
undetermined strokes, 76 (58%) were predicted to be CE, 24 
(18,3%) were LAA, 15 (11,5%) were lacunar and 16 (12,2%) 
remained unknown [77].  
 As authors discussed, these studies have some limitations 
being the small population size the most important. How-
ever, they evidenced that gene expression profile could allow 
us to distinguish between different causes of stroke. With the 
development of point-of-care devices, based on fast analysis, 
cryptogenic stroke clarification and preventive stroke treat-
ments could be further improved. 
STROKE ETIOLOGY AND CIRCULATING mi-
croRNA  
 microRNAs (miRNAs) are small (19-25 nt length) non-
coding RNAs involved in the post-transcriptional regulation 
of genes by inhibition or degradation of mRNA. miRNAs are 
single stranded molecules of RNA whose high stability al-
lows its detection in serum or plasma. Moreover, their ex-
pression patterns may reflect underlying pathophysiological 
processes. These important features make miRNAs very at-
tractive biomarkers for human diseases [79].  
 Unfortunately, just a few studies have attempted to find 
differential miRNA levels between patients and controls. 
The study conducted by Gan and colleagues is an example. 
They measured blood levels of miRNA-145 (a modulator of 
vascular smooth muscle cells phenotype) and showed an up-
regulation in stroke [80]. On the other hand, Zeng analyzed 
blood miRNA-210 and found it decreased in patients with 
ischemic stroke when compared to healthy controls 
(p=0.001) even after 14 days from stroke onset [81].  
 Among etiologies, until now only one study has focused 
on finding differences on miRNAs expression [82]. This 
study, conducted by Tan and collaborators, assessed differ-
ential miRNA profile and reported a list of 132 miRNAs 
with altered expression depending on stroke etiology. Some 
of them were up-regulated with a fold change >2 in only one 
subtype. This is the case of 7 miRNAs (miR-130b, -29b, -
301a, -339-5p, -532-5p, - 634 and 886-5p) more expressed in 
SVD. Moreover, cluster analysis on different miRNA pro-
files among etiologies showed that undetermined stroke pro-
files were similar to SVD, suggesting that studied patients 
with undetermined etiology have resulted from SVD. Hence 
it might be assumed that miRNA profiling could be used to 
differentiate CE, LAA or SVD strokes from each other and 
to resolve undetermined strokes. 
 In contrast to the small number of published studies of 
miRNA focused on stroke etiologies, numerous studies 
have documented a relation between some specific miRNA 
and AF, strongly related with CE stroke [83]. Very re-
cently, Liu Z and collaborators examined miRNA expres-
sion profiles in 3 groups: 5 patients with paroxysmal AF, 5 
with persistent AF and 5 healthy controls. They found sub-
stantially lower levels of miRNA-150 in both groups of AF 
patients when compared with controls (p<0.001) and was 
identified as a predictor of AF (OR 1.96, 95% CI 1.5 to 
3.57, p<0.001) [84]. Other authors have evidenced the in-
volvement of miRNAs in basic mechanisms of AF. Adam and 
colleagues found an increased expression on miRNA-21 and a  
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Biomarker Levels in AF Main Function Ref. 
Adiponectin Q15848 384 Persistent AF > paroxysmal AF and control subjects 
Adipokine involved in the control of fat metabolism and 
insulin sensitivity.  [64, 65] 
ADMA - 42 Acute AF > chronic AF and 
controls 
Endogen inhibitor of NOS. ADMA contributes to throm-
boembolism in AF. 
[47] 
Ang-2 Q15123 59 AF > control subjects Angiogenic factor.  [66] 
Apelin Q9ULZ1 166 AF < sinus rhythm or con-
trol subjects 
May have a role in the control of body fluid homeostasis.  [67,68] 
CD63* P08962 121 AF > control subjects Platelet activation marker. [69] 
E-selectin* P16581 145 AF > control subjects Marker of endothelial activation.  [42] 
Fibrinopeptide A P02671 83 AF ↑ Released as part of blood clotting process. It reflects 
thrombin activity. 
[59] 
IL-18 Q14116 56 Persistent AF > paroxysmal 
AF and sinus rhythm 
Pro-inflammatory cytokine.  [41] 
MMP-1 P03956 48 AF < control subjects Cleaves collagen types I, II and III.  [70] 
MMP-2 P08253 364 AF > sinus rhythm Degrades extracellular matrix in remodeling of vascula-
ture, angiogenesis and tissue repair.  
[43,71] 
MMP-3 P08254 86 AF > sinus rhythm Degrades fibronectin, laminin, gelatins and collagens.  [71] 
MMP-9 P14780 364 AF > control and sinus 
rhythm subjects 
Proteolyses extracellular matrix.  [41,71,72] 
NPY P01303 222 AF > control subjects Implicated in the control of feeding and in secretion of 
gonadotrophin-releasing hormone.  
[72] 
Osteoprotegerin O00300 2863 Associated with AF Neutralizes osteoclastogenesis.  [73] 
PF-4 P02776 26 AF > control subjects Marker of platelet activation in AF patients. [44] 
PMP - 20 AF > control subjects PMPs play a role in hemostatic response to vascular injury.  [46] 
Prothrombin frag-
ment 1.2 (F1+2) 
- 48 AF > control subjects Marker of thrombogenesis [59] 
p-selectin (CD62P) P16109 121 AF > control subjects Mediates the interaction of activated endothelial cells or 
platelets with leukocytes 
[69] 
SDMA - 394 AF > non-AF It influences NO formation via inhibition of L-arginine 
uptake.  
[48] 
sVCAM-1 P19320 278 Associated with AF Important in cell-cell mediation. [43] 
sP-selectin P16109 90 AF > control subjects Mediates interaction of activated endothelial cells or plate-
lets with leukocytes.  
[45] 
TGF-β P01137 107 AF < non-AF Controls proliferation, differentiation and other functions 
in many cell types.  
[74] 
TIMP-1 P01033 
134 AF > sinus rhythm patients 
and control subjects Irreversibly inactivates metalloproteinases.  [70, 71] 
Troponin I P48788 
6189 AF ↑ Inhibitory subunit of troponin. Increased troponin I associ-
ated with an increase in the risk of stroke or systemic 
embolism and vascular events. 
[75] 
VEGF P15692 72 Paroxysmal and persistent 
AF > control subjects 
Pro-angiogenic factor.  [76] 
Ang: Angiopoietin; ADMA: Asymmetric dimethylarginine; SDMA: Symmetric dimethylarginine: CITP: Carboxy-terminal telopeptide of collagen type I; MMP: Matrix metalloprote-
inase; TIMP-I: Tissue inhibitor of metalloproteinases; IL: Interleukin; NPY: Neuropeptide Y; PF-4: Platelet factor 4; PMP: Platelet microparticle; TF: Transferrin; TGF-β: Transform-
ing growth factor beta; VEGF: Vascular endothelial growth factor; sVCAM-1: soluble vascular cell adhesion molecule 1; sCD40L: soluble CD40 ligand; NOS: Nitric oxide synthase. 
*Candidate marker with controversial results among studies. 
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decreased expression of protein Sprouty1 (downstream 
target of miRNA-21) in left atria of patients with AF [85]. 
They also showed a reduction of AF by miRNA-21  
inhibition, evidencing its important role in atrial fibrosis 
regulation. 
 The results of these studies suggest, on one hand, the 
use of miRNA as plasma biomarkers for AF detection and 
consequently the identification of an embolic source in 
undetermined strokes; on the other hand, they open the 
door to potential therapeutic targets by direct miRNA si-
lencing. 
STROKE ETIOLOGY AND GENE POLYMOR-
PHISMS  
 To date several studies have been performed to further 
understand the genetic basis of ischemic stroke. The most 
promising results have been obtained from projects that 
performed Genome Wide Analysis (GWA) approaches. 
The International Stroke Genetics Consortium (ISGC) and 
the Wellcome Trust Case Control Consortium 2 
(WTCCC2) conducted a GWA study on three stroke sub-
types: LAA, SVD and CE stroke [86]. This was a large 
study with a discovery association phase conducted in 3548 
affected individuals and 5972 controls, and a second repli-
cation phase performed in 5859 cases and 6281 controls. 
Some previously reported associations were replicated in 
this analysis such as the single nucleotide polymorphisms 
(SNPs) rs1906599 and rs12932445, located in the PITX2 
(Paired-like homeodomain 2) and ZFHX3 (Zinc finger ho-
meobox 3) genes respectively, and both related with CE 
etiology; or the SNP rs2383207 located in the 
CDKN2A/CDKN2B (Cyclin-dependent kinase inhibitor 2) 
gene, related with LAA stroke. Interestingly, a previously 
unknown association between LAA stroke and the SNP 
rs11984041 (located within the final intron of the HDAC9 
(Histone deacetylase 9) gene) was firstly identified in this 
study. Finally, a third additional verification step was per-
formed in 735 LAA cases and 28583 controls which further 
confirmed previous data. Taken together, the results from 
the discovery and two-steps verification phases provide 
strong evidence for association between the new SNP 
rs11984041 and LAA stroke (p=1.87x10-11) and further 
confirmed the association between CE stroke etiology and 
previously identified polymorphism in genes PITX2 and 
ZHF3.  
 Other studies have been carried out with approaches 
different from GWA, identifying other SNPs related to 
stroke etiology subtypes, e.g. rs2020918 related with SVD 
[87, 88], or rs315934, rs1180243, rs2071373 associated 
with a decrease in LAA stroke [89]. In spite of being size-
limited and needing replication in further steps, these 
studies provide helpful information as a basis for future 
GWA of polymorphisms related to stroke etiologies.  
 Other polymorphisms different from single nucleotide 
ones have been analyzed and observed to be specifically 
associated with a stroke subtype. For instance, a 32 base-pair 
deletion in CCR5 (Chemokine C-C motif receptor 5) gene 
(Δ32 polymorphism) is considered to exert a protective  
 
effect against CE stroke as it has lower frequency in this 
subtype (OR, 0.4; 95% CI, 0.24-0.79; p=0.008) than in LAA, 
SVD or cryptogenic strokes [90].  
 Although blood proteins, nucleic acids and even gene 
expression profiles may aid in the diagnosis and decision-
making during acute and subacute phases of stroke, ge-
netic biomarkers specific for each etiology provide valu-
able evidence before stroke occurrence allowing physi-
cians to prescribe the most suitable preventive treatment. 
Furthermore, the identification of genetic signatures of 
each etiology may be of main interest in guiding undeter-
mined stroke diagnosis, especially during subacute phase 
when it becomes primordial an optimal secondary preven-
tion to minimize recurrences. Table 4 shows a compila-
tion of CE stroke and AF related genes, miRNA and po-
lymorphisms. 
FUTURE PERSPECTIVES 
 During the last years, a great number of studies have 
been conducted aiming to find new biomarkers that could 
aid in the differentiation of ischemic stroke etiologies. 
Although some of these studies have shown markers with 
high sensitivity and specificity, in a large cohort of pa-
tients and proving to be independent predictors of 
ischemic stroke, there are still some hurdles to take over 
before implementing them to daily clinical routine. Table 
5 shows the general strengths and shortcomings of the 
studies on stroke etiology biomarkers.  
 Recent advances achieved in proteomics in the last 
few years have brought new approaches for the identifica-
tion of biomarkers. The use of quantitative proteomics has 
proven to be a promising strategy for identifying potential 
biomarkers for a number of diseases such as cancer, infec-
tious diseases or autoimmunity. The stroke field can also 
take benefit from this fast development since recent stud-
ies have reported very promising results mainly directed 
at diagnosis. Dawson and collaborators explored the uri-
nary proteome from ischemic stroke and transient 
ischemic attack patients versus controls. They developed 
two biomarker-based classifiers with identified proteins 
and validated them in independent blinded samples, show-
ing a clear association of these biomarkers and stroke 
[91]. Dayon and colleagues also analyzed proteins from 
brain extracellular fluid and identified stroke-related pro-
teins (i.e. glutathione S-transferase, or peroxiredoxin-I) 
that were further validated [92]. The same strategies could 
be followed on selected patients with clear etiologic pro-
file to detect new candidate markers for each stroke sub-
type. Once replicated and validated, the combination of 
different biomarkers in a diagnostic test would provide 
the most valuable approach to accurately identify stroke 
etiology. However, neither biomarker nor panel of bio-
markers has still showed enough sensitivity and specific-
ity to improve clinical predictor models. New statistical 
tools, such as net reclassification improvement (NRI) and 
integrated discrimination improvement (IDI) indexes, 
have been developed to evaluate the added value of a 
biomarker or combination of biomarkers to the clinical  
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basis [93, 94]. If biomarkers demonstrated its role, these 
improved prediction models would help to reclassify pa-
tients according with the risk of suffering a cardiac embo-
lism. Thus the rate of undetermined strokes might be re-
duced and a faster decision-making in pharmacological 
secondary prevention could be done. 
 At a genetic level, recent studies in transcriptomic and 
specially those performed through GWA approaches have 
provided new stroke and even etiology-related markers. 
These newly described genetic markers may not only aid in 
the diagnosis or patient etiologic classification, but also may 
serve as future therapeutic targets for each stroke etiologic 
subtype. 
 Despite having found many encouraging candidates by 
all these approaches their clinical application requires sev-
eral careful validation steps. Multi-centric studies, with 
greater cohorts of patients, supported by multiple replica-
tions and performed with tools for massive molecular and 
genetic analysis will be the base to increase the output of 
potential biomarkers that may be implemented in daily 
clinical practice. 
 
Table 4. Genes, miRNA and polymorphisms candidates to become biomarkers of CE stroke: 
Genes associated with CE stroke 
Candidate 
Molecule 
Entrez Gene Sample 
Size 
Reason for Being a Candidate Ref .
ENPP2 5168 33 Regulates lysophosphatidic acid production. It has Angiogenic properties.  [77] 
GRM5 2915 33 Modulates normal brain function. [77] 
LHFP 10186 33 Involved in cardiac proliferation.  [77] 
TMEM19 55256 33 Cardiovascular development and haematological system function.  [77] 
EBF1 13591 33 Involved in haematological system development and function.  [77] 







Reason for Being a Candidate Ref. 
miRNA-
145 
MI0000461 32 Regulates the smooth muscle cells differentiation. Up-regulated in ischemic stroke patients when 




MI0000286 112 It is strongly linked to hypoxia pathways, and it is up-regulated in response to hypoxia-inducible factors. 
Decreased expression in ischemic stroke compared with control subjects. 
[81] 







Reason for being a candidate Ref .
miRNA-
150 
MI0000479 10 Regulates hematopoiesis by modulating stem cell differentiation to megakaryocytes. Lower levels in AF 
patients than control subjects 
[84] 
miRNA-21 MI0000077 10 Regulates atrial fibrosis. Increased plasma levels than control subjects. [85] 





Reason for Being a Candidate Ref. 
PITX2 rs1906599 3548 
Controls cell proliferation in a tissue-specific manner and is involved in morphogenesis. SNP associated 
with CE stroke. 
[86] 
ZFHX3 rs12932445 3548 Transcriptional repressor. Regulator of myoblasts differentiation. SNP associated with CE stroke. [86] 
CCR5 - 478 Δ32 polymorphism (32 bp deletion) associated with lower risk of CE stroke than LAA, SVD and 
cryptogenic subtypes. 
[90] 
ENPP2: Ectonucleotide pyrophoshpatase/phosphodiesterase family member 2; GRM5: Glutamate receptor metabotropic 5; LHFP: lipoma HMGIC fusion partner; TMEM19: trans-
membrane protein 19; EBF1: early B-cell factor 1; PITX2: Paired-like homeodomain 2; ZFHX3: Zinc finger homeobox 3; CCR5: Chemokine C-C motif receptor 5; SNP: single 
nucleotide polymorphism; CE: cardioembolic; LAA: large artery aterothrombotic; SVD: small vessel disease. 
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Table 5. General pro’s and con’s of studies conducted aiming to find ischemic stroke etiology biomarkers. 
Strenghts Shortcommings 
- Some published studies include large cohorts (n>200 patients). 
- The great majority of studied biomarkers for stroke etiology can be 
easily determined in blood samples. 
- The most promising biomarkers are related to specific chronic 
condition prior to brain artery occlusion (i.e. cardiac dysfunctions or 
insufficiency). 
- Some biomarkers, especially when combined, have showed high 
sensitivity and specificity for cardioembolic stroke i.e D-dimer & 
BNP combination [24], NT-proBNP [27], etc  
- Some biomarkers have been proven to clear up undetermined strokes, 
i.e D-dimer & BNP combination [24] or a panel including 40 genes 
expression profile [77]. 
- Most of those studies show optimal cutoff points for the studied 
biomarkers and perform logistic regression models to find out if a 
biomarker might independently predict cardioembolic stroke. 
- Some of the markers may be determined some days after the acute 
event and still have an acceptable predictive value.  
- Relevant clinical decisions may be done using these markers (i.e. to 
shift antiplatelet to anticoagulant regime).  
 
- There is currently no “gold-standard” to define the exact 
etiology/mechanism of stroke. 
- Some underlying conditions i.e. inflammation, endothelial damage are 
common among different stroke etiologies, making some of the 
biomarkers unspecific.  
- The clot formation usually occurs hours before sample collection. 
Therefore, a biomarker specifically related to this event might be partly 
cleared from circulation at that time. 
- Most of times samples are taken after 4.5 hours, thus currently the great 
majority of the studied biomarkers might not be useful during acute 
phases. 
- Most published studies do not report temporal profiles of the biomarker 
after stroke onset and among etiologies, therefore the ideal time point 
of the biomarker to be used remains elusive. 
- Biomarker studies, especially those with small sample size, do not 
show a biomarker cutoff point and a logistic regression analysis nor 
other statistical metrics (i.e. IDI). 
- Cardioembolic related biomarkers might be also associated with the 
cardiovascular disorders originating the index stroke. 
- Ongoing therapies prior to stroke onset are not always taken into 
account in patient’s selection criteria. Previous anticoagulation or 
antiplatelet therapies might influence biomarker levels. 
- Clinical models are not always adjusted by NIHSS and infarct size. As 
CE stroke is more pronounced than other etiologies it might be a 
confounder to be taken into account. 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